

Venkata Narayana Are,^a Biplab Ghosh,^a Ashwani Kumar,^a Pooja Yadav,^a Deepak Bhatnagar,^b Sahayog N. Jamdar^{c*} and Ravindra D. Makde^{a*}

^aHigh Pressure and Synchrotron Radiation Physics Division, Bhabha Atomic Research Centre, Trombay, Mumbai, Maharashtra 400 085, India, ^bSchool of Biochemistry, Devi Ahilya University, Indore 452 001, India, and ^cFood Technology Division, Bhabha Atomic Research Centre, Trombay, Mumbai, Maharashtra 400085, India

Correspondence e-mail: snjam@barc.gov.in, ravimakde@rrcat.gov.in

Received 26 June 2014
Accepted 4 August 2014


Expression, purification, crystallization and preliminary X-ray diffraction analysis of acylpeptide hydrolase from *Deinococcus radiodurans*

Acylpeptide hydrolase (APH; EC 3.4.19.1), which belongs to the S9 family of serine peptidases (MEROPS), catalyzes the removal of an *N*-acylated amino acid from a blocked peptide. The role of this enzyme in mammalian cells has been suggested to be in the clearance of oxidatively damaged proteins as well as in the degradation of the β -amyloid peptides implicated in Alzheimer's disease. Detailed structural information for the enzyme has been reported from two thermophilic archaea; both of the archaeal APHs share a similar monomeric structure. However, the mechanisms of substrate selectivity and active-site accessibility are totally different and are determined by inter-domain flexibility or the oligomeric structure. An APH homologue from a bacterium, *Deinococcus radiodurans* (APHdr), has been crystallized using microbatch-under-oil employing the random microseed matrix screening method. The protein crystallized in space group $P2_1$, with unit-cell parameters $a = 77.6$, $b = 189.6$, $c = 120.4$ Å, $\beta = 108.4^\circ$. A Matthews coefficient of 2.89 Å³ Da⁻¹ corresponds to four monomers, each with a molecular mass of ~ 73 kDa, in the asymmetric unit. The APHdr structure will reveal the mechanisms of substrate selectivity and active-site accessibility in the bacterial enzyme. It will also be helpful in elucidating the functional role of this enzyme in *D. radiodurans*.

1. Introduction

Acylpeptide hydrolase (APH; EC 3.4.19.1), also referred to as acylaminoacyl peptidase, is a member of the S9 family of serine proteases that use a unique Ser-Asp-His catalytic triad for the hydrolysis of peptides (MEROPS database; Rawlings *et al.*, 2014). It catalyzes the removal of an *N*-acylated amino-acid residue from a blocked peptide, producing an acylamino acid and a peptide with a free amino-terminus. It cleaves a variety of peptides with different *N*-terminal acyl groups such as acetyl, chloroacetyl, formyl and carbamyl, including a bioactive peptide (α -melanocyte-stimulating hormone; Jones *et al.*, 1986). In addition to exopeptidase activity, APH homologues from mammals and archaea have also been shown to possess low levels of endopeptidase activity (Fujino *et al.*, 2000; Kiss *et al.*, 2007). Indirect evidence suggests that APH enzymes play important roles in the cellular physiology of mammals. For example, in human erythrocytes this enzyme preferentially cleaves oxidatively damaged and glycosylated proteins (Fujino *et al.*, 2000). Moreover, the enzyme also degrades β -amyloid peptide, a pathogenic fragment associated with Alzheimer's disease (Yamin *et al.*, 2009). A truncated form of the APH homologue in mice (55 kDa) cleaves the lens β 2-crystallin protein, resulting in the accumulation of low-molecular-weight peptides that promote cataract formation (Santhoshkumar *et al.*, 2014).

APH homologues are ubiquitous in distribution and have been identified in genomes from all three domains of life: bacteria, archaea and eukaryotes. Biochemical characterizations of APH enzymes have been reported from thermophilic archaea, mammals and plants (Abraham & Nagle, 2013), while crystal structures have been reported from two genera of archaea (Bartlam *et al.*, 2004; Menyhárd *et al.*, 2013). APH and other proteins of the S9 family share a similar monomeric structure consisting of two domains: an *N*-terminal seven-bladed or eight-bladed β -propeller and a catalytic α/β -hydrolase



© 2014 International Union of Crystallography
All rights reserved

Table 1
Macromolecule-production information.

Source organism	<i>D. radiodurans</i> R1
DNA source	Bacterial cells
Forward primer	CGTGGATCCAAACAATTCCGAAACCCCGGCC
Reverse primer	CGTTGTACATTACAGCCAGCGTTCAGCCAGG
Cloning vector	None
Expression vector	pST50Tr
Expression host	<i>E. coli</i> BL21(DE3)pLysS
Complete amino-acid sequence of the construct produced	MASWSHPQFEKGS SHHHHHSSGGGGG ENLYFQGSNNSET-PAPGPD SL LALAFPSDPQVSPDGKQVAFVLAQISEEDPAK-PDKDFARPRYRSGLWLEGGGAARPLTHAETGRGDSAPRWS-PDGNLAFVRSAGEVKAALMLLPLKGGEARRVTHFKNGVSGPQWSPDGRFIAFTTTADTEDKRDGEREARLVTRPVYRANGADWLPERPAALWLYDVEADKLEWYAPEIGIGALS W WPD-SRGVLLIVQSEDEWQASQWRQDVYDLPLPTADAPAAPQKLL-DWNSAAHGLAPHDPGGRFALIGRPAGKNT EA HL YL IEN-GQHRRLDTGHDHPVGDVAVGGDCHVAFPEGRWLDGDTLL-FSSTVRGSGVGLFTAHI GG VKAYDHD P QGVISAFTANEHG-VALIRESATRFEVELNGQRVTDLHARFPFVREPQRVTF-ETELGE GE GWLLPEGEQKVPALLNHGGPHTDYGHGFTH-EFQLMAARGYVCYSNPRGSVGYGQAVVDAIYGRWGTVDADDLLNFFDRCLEAVPRLDAAKTAVMGGSYGGFMTNWI T GHTTRFQAAITDR CI SNLISFGGTSIDIGLRFWDELGLDFSR-RADALKLWDLSP L QVENVKTP TL I V HSVLDHRC P VEQAE-QWYALHKHQV VP VRFRFPEE N HEL S RSGR P DR RL TRLNE-YFAWLERWL

domain. However, the proteins have evolved different mechanisms to shield the active site to avoid the degradation of nontargeted cellular proteins. The mechanisms for substrate selectivity and access to the active sites vary across the archaeal APHs and the other S9 family enzymes (Fülöp *et al.*, 2000; Aertgeerts *et al.*, 2004; Shan *et al.*, 2005; Harmat *et al.*, 2011; Menyhárd *et al.*, 2013).

Deinococcus spp. are extremely radiation-resistant. One of the mechanisms for this exceptional resistance is the protection of the proteome against the oxidative damage caused by ionizing radiation (Krisko & Radman, 2013). A possible role of APH homologues in eliminating oxidized proteins has been suggested in mammalian cells (COS-7) under oxidative stress (Shimizu *et al.*, 2003). Thus, from this viewpoint, it is important to study this enzyme from *D. radiodurans*. Here, we report the crystallization and preliminary X-ray diffraction studies of the APH homologue from the bacterium *D. radiodurans* (APHdr; GenBank accession No. NP_293889). The structural studies will be useful in elucidating the mechanisms of substrate-size selectivity and active-site accessibility in the bacterial APH enzyme and will also be helpful in understanding the functional role of this enzyme in *D. radiodurans*.

2. Materials and methods

2.1. Macromolecule production

The coding DNA sequence (CDS) of a gene encoding the APHdr protein (GenBank accession No. NP_293889) was PCR-amplified from the genomic DNA of *D. radiodurans* R1 (NCBI taxonomic ID 243230). The oligos flanking the CDS, opx175 (CGTGGATCCAAACAATTCCGAAACCCCGGCC) and opx176 (CGTTGTACATTACAGCCAGCGTTCAGCCAGG), containing *Bam*HI and *Bsr*GI restriction-enzyme sites, respectively, were used to PCR-amplify the CDS using *Pfu* DNA polymerase (Table 1). The CDS was cloned into pST50Tr, a T7-promoter-based expression plasmid (Tan *et al.*, 2005), so as to form an in-frame translational fusion of APHdr with a Strep-tag II-hexahistidine-*Tobacco etch virus* protease site tag (STRHISTEV; 3.8 kDa). The cloning and expression hosts used in the present studies were *Escherichia coli* strains XL1 Blue and BL21(DE3)pLysS, respectively. The identity and integrity of the construct was verified by restriction-digestion analysis and DNA

Table 2
Crystallization.

Method	Microbatch-under-oil
Plate type	96-well U-bottom plate
Temperature (K)	293
Protein concentration (mg ml ⁻¹)	15
Buffer composition of protein solution	20 mM Tris-HCl pH 8.0, 200 mM NaCl
Composition of reservoir solution	50 mM sodium acetate pH 4.5, 200 mM NaCl, 10 mM magnesium chloride, 20% PEG 3350
Volume and ratio of drop	2 µl (1:1)
Volume of reservoir	Nil (microbatch)

sequencing using flanking T7 and T7-terminator oligos. The expressing clone was grown in 5 l 2×TY broth at 310 K until the OD₆₀₀ reached 0.4 and was then shifted to 301 K for further growth. The culture was then induced at an OD₆₀₀ of ~0.8 for 18 h by the addition of 0.2 mM isopropyl β-D-1-thiogalactopyranoside (IPTG). The cells were harvested by centrifugation at ambient temperature and the pellet was immediately suspended in P300 buffer (50 mM sodium phosphate pH 7.0, 300 mM NaCl). The cells were disrupted by sonication. The soluble fraction of the cell lysate containing the desired protein (STRHISTEV-APHdr) was subjected to metal-ion affinity chromatography by the batch method at 277 K. The lysate was mixed with ~10 ml of equilibrated Ni Sepharose resin (GE Healthcare). The bound proteins on the resin were eluted with P300 buffer containing 500 mM imidazole. The eluted protein (STRHISTEV-APHdr) was subjected to digestion by *Tobacco etch virus* protease (TEV; 1:50 molar ratio) at 293 K while dialyzing against T200 buffer (20 mM Tris-HCl pH 8.0, 200 mM NaCl) for 48 h. The desired protein (APHdr) was separated from the STRHISTEV peptide tag and undigested protein using a 5 ml HisTrap column on an ÄKTA system (GE Healthcare) at ambient temperature. The purified protein was concentrated to greater than 16 mg ml⁻¹ using a 30 kDa cutoff ultrafiltration device (Sartorius). Glycerol was added to the protein solution to 20% (v/v) and it was then aliquoted and stored at 203 K until further use. Size-exclusion chromatography was performed with T200 buffer on a Superdex 200 10/300 GL column using an ÄKTA purifier system (GE Healthcare).

2.2. Crystallization

For the crystallization experiment, an aliquot of stored protein was subjected to dialysis using T200 buffer. The equilibrated protein was concentrated to ~15 mg ml⁻¹ for setting up crystallization trials. Initial crystallization trials were set up employing the commercial crystallization screens Index (Hampton Research) and JCSG-*plus* (Molecular Dimensions). Crystallization was carried out at 293 K employing the microbatch-under-oil method (Chayen *et al.*, 1992), in which 1 µl protein solution was mixed with 1 µl crystallization solution and overlaid with 50 µl Al's oil [1:1(v:v) silicone oil:mineral oil] in 96-well U-bottom plates. A single crystal hit was observed in one of the JCSG-*plus* crystallization conditions [0.1 M bis-tris pH 5.5, 0.2 M ammonium sulfate, 25% (w/v) polyethylene glycol (PEG) 3350]. The thin plate-like crystals were of poor quality and the crystallization condition was not further optimized. Instead, we used these crystals for microseeding employing the random microseed matrix screening method (D'Arcy *et al.*, 2007). In this method, nuclei formed using one crystallization condition are transferred to other random crystallization conditions to screen for a condition that supports crystal growth. The microseeds were introduced into drops (pre-equilibrated for 5 d) of a factorial screen by streak-seeding. The factorial screen was prepared in-house using combinations of buffers (of different pHs), monovalent and divalent ions and different PEG 3350 concentrations. The microseeding yielded crystals of different sizes

and shapes in seven different crystallization conditions from our factorial screen, three of which produced crystals that were suitable for diffraction studies. The crystals exhibiting the best diffraction resolution were grown from the crystallization condition 50 mM sodium acetate pH 4.5, 200 mM NaCl, 10 mM magnesium chloride, 20% (w/v) PEG 3350 (Table 2). The crystals were cryoprotected using Parabar 10312 oil (Hampton Research). They were picked out from the microbatch drops with a cryoloop, rinsed for 1–2 min in Parabar 10312 oil to remove excess mother liquor and then flash-cooled in liquid nitrogen.

2.3. Data collection and processing

The single-crystal diffraction experiments on protein crystals were carried out on the recently commissioned protein crystallography (PX-BL21) beamline at the 2.5 GeV Indus-2 synchrotron, India. The diffraction images were collected from a cryocooled crystal (100 K) using 1° oscillation at a wavelength of 0.97947 Å on a MAR225 CCD (Rayonix) detector. The crystal diffracted to 2.6 Å resolution. The data were indexed and integrated using *XDS* (Kabsch, 2010) and subsequently scaled using *AIMLESS*. The intensity data statistics are summarized in Table 3. Self-rotation function calculations were performed using *POLARRFN*. A molecular-replacement solution was obtained using *Phaser* (McCoy *et al.*, 2007). *AIMLESS*, *POLARRFN* and *Phaser* were used as part of the *CCP4* package (Winn *et al.*, 2011).

3. Results and discussion

The typical yield of the purified protein (APHdr) was found to be ~60 mg per litre of bacterial culture. The purified protein showed a single symmetric peak on Superdex 200 size-exclusion chromatography corresponding to a molecular mass of 265 kDa (Fig. 1). This observed molecular mass matches reasonably well with the molecular mass calculated for an APHdr tetramer (291 kDa) from the protein




Figure 1 Gel-filtration profile of APHdr (marked by an arrow) using a Superdex 200 column with 20 mM Tris-HCl pH 8.0, 200 mM NaCl. The column was calibrated using proteins of standard molecular mass (Sigma; catalogue No. MWGF200-1KT). The observed molecular mass of APHdr is 265 kDa (marked by an arrow in the upper inset). A 15% SDS-PAGE of purified APHdr is shown in the lower inset; lane 1 contains standard molecular-mass markers (labelled in kDa) and lane 2 contains APHdr protein.

Table 3 Data collection and processing.

Values in parentheses are for the outer shell.	
Beamline	PX-BL21, Indus-2, India
Wavelength (Å)	0.97947
Resolution (Å)	47.96–2.60 (2.64–2.60)
Temperature (K)	100
Space group	<i>P</i> 12 ₁
Unit-cell parameters (Å, °)	<i>a</i> = 77.6, <i>b</i> = 189.6, <i>c</i> = 120.4, $\alpha = \gamma = 90, \beta = 108.4$
Total No. of reflections	240282 (11801)
No. of unique reflections	96084 (4810)
Multiplicity	2.5 (2.5)
<i>R</i> _{meas} † (%)	12.2 (60.4)
$\langle I/\sigma(I) \rangle$	10.2 (2.6)
Completeness (%)	95.1 (96.8)
Matthews coefficient (Å ³ Da ⁻¹)	2.89
Solvent content (%)	58
No. of monomers in the asymmetric unit	4
Overall <i>B</i> factor from Wilson plot (Å ²)	27.42

$$\dagger R_{\text{meas}} = \frac{\sum_{hkl} \{N(hkl)/[N(hkl) - 1]\}^{1/2} \sum_i |I_i(hkl) - \langle I(hkl) \rangle|}{\sum_{hkl} \sum_i I_i(hkl)}$$

sequence. It thus confirms the existence of APHdr in a tetrameric form in the given conditions. The purified APHdr enzyme was found to be active towards *N*-CBZ-L-Ala-*p*-nitrophenyl ester, with an enzymatic efficiency (k_{cat}/K_m) of about 132 mM⁻¹ s⁻¹ (unpublished results). Initial crystallization screening produced thin plate-like crystals with inferior morphology in the JCSG-*plus* crystal screen. When these crystals were used as a source of microseeds in 96 different conditions of a factorial screen produced in-house using the random microseed matrix screening method, crystals were yielded in seven different crystallization conditions. The crystals which gave the best diffraction resolution were grown from the crystallization condition 50 mM sodium acetate pH 4.5, 200 mM NaCl, 10 mM magnesium chloride, 20% PEG 3350 (Fig. 2). Data were collected to a resolution of 2.6 Å at 100 K. The unit-cell parameters were *a* = 77.6, *b* = 189.6, *c* = 120.4 Å, $\beta = 108.4^\circ$ and the crystals belonged to space group *P*2₁. The expected molecular mass of monomeric APHdr deduced from its sequence is 72.64 kDa. The Matthews coefficients (*V*_M; Matthews, 1968) calculated from the unit-cell parameters were 2.89 and 2.31 Å³ Da⁻¹ for four and five monomers in the asymmetric unit, respectively. The ambiguity of four or five monomers in the asymmetric unit was resolved using a self-rotation function and the




Figure 2 An APHdr protein crystal grown from the crystallization condition 50 mM sodium acetate pH 4.5, 200 mM NaCl, 10 mM magnesium chloride, 20% (w/v) PEG 3350.




Figure 3 Self-rotation function ($\kappa = 180^\circ$ section) calculated using *POLARRFN* in *CCP4* (Winn *et al.*, 2011) in the resolution range 20–3.0 Å with an integration radius of 20 Å; the contour starts at 30% with an interval of 5%. The ω angle varies in the radial direction and the φ angle varies along the circumference. Two peaks (marked by arrows) at $\omega = 18.5^\circ$, $\varphi = 180^\circ$ and $\omega = 71.4^\circ$, $\varphi = 0^\circ$, each with 71% of the magnitude of the origin peak, represent twofold noncrystallographic symmetry (NCS) axes.

size-exclusion chromatography results. A self-rotation function calculated using *POLARRFN* showed the presence of twofold noncrystallographic symmetry (NCS) axes in the *ac* plane perpendicular to the crystallographic *b* axis (Fig. 3). The twofold NCS axes are most probably owing to the presence of four monomers rather than five monomers in the asymmetric unit, which is consistent with the tetrameric nature of the protein as deduced from size-exclusion chromatography. The closest sequence homologue of APHdr in the Protein Data Bank (PDB) is acylaminoacyl peptidase from *Pyrococcus horikoshii* (APHph; PDB entry 4hxg; Menyhárd *et al.*, 2013), with which it shares ~29% sequence identity. Molecular replacement (MR) in *Phaser* using a monomer of APHph as a search model gave a unique solution with a final LLG score of 804. The MR solution consists of four monomers in the asymmetric unit of space group *P*₂₁. This is in complete agreement with the gel-filtration and self-rotation function analysis. Initial refinement of the structure solution using *PHENIX* (Adams *et al.*, 2010) resulted in an *R*_{work} and *R*_{free} of 31 and 36%, respectively. Further structure refinement and model building are in progress. Structural analysis of APHdr will reveal the mechanism of substrate selectivity, size exclusion and access to the active site in the tetrameric form of APH enzymes. Additionally,

structure–function information on APHdr will shed light on its possible role in the degradation of oxidatively damaged proteins in *D. radiodurans*, which is known to undergo severe oxidative stress on exposure to ionizing radiation.

We thank Dr S. M. Sharma for his constant support and for leading the development and commissioning of the protein crystallography beamline at the Indus-2 synchrotron, RRCAT, India. We sincerely thank Drs P. D. Gupta, S. K. Deb and G. S. Lodha for providing the necessary support and infrastructure at Raja Ramanna Centre for Advanced Technology, Indore to carry out this research. We thank the staff at Indus-2 for providing the synchrotron beam for the present work. We are highly grateful to S. K. Bhattacharjee for his support during the work.

References

- Abraham, C. R. & Nagle, M. W. (2013). *Handbook of Proteolytic Enzymes*, edited by N. D. Rawlings & G. Salvesen, pp. 3401–3403. New York: Academic Press.
- Adams, P. D. *et al.* (2010). *Acta Cryst.* **D66**, 213–221.
- Aertgeerts, K., Ye, S., Tennant, M. G., Kraus, M. L., Rogers, J., Sang, B.-C., Skene, R. J., Webb, D. R. & Prasad, G. S. (2004). *Protein Sci.* **13**, 412–421.
- Bartlam, M., Wang, G., Yang, H., Gao, R., Zhao, X., Xie, G., Cao, S., Feng, Y. & Rao, Z. (2004). *Structure*, **12**, 1481–1488.
- Chayen, N. E., Shaw Stewart, P. D. & Blow, D. M. (1992). *J. Cryst. Growth*, **122**, 176–180.
- D’Arcy, A., Villard, F. & Marsh, M. (2007). *Acta Cryst.* **D63**, 550–554.
- Fujino, T., Watanabe, K., Beppu, M., Kikugawa, K. & Yasuda, H. (2000). *Biochim. Biophys. Acta*, **1478**, 102–112.
- Fülöp, V., Szeltner, Z. & Polgár, L. (2000). *EMBO Rep.* **1**, 277–281.
- Harmat, V., Domokos, K., Menyhárd, D. K., Palló, A., Szeltner, Z., Szamosi, I., Beke-Somfai, T., Náray-Szabó, G. & Polgár, L. (2011). *J. Biol. Chem.* **286**, 1987–1998.
- Jones, W. M., Manning, L. R. & Manning, J. M. (1986). *Biochem. Biophys. Res. Commun.* **139**, 244–250.
- Kabsch, W. (2010). *Acta Cryst.* **D66**, 125–132.
- Kiss, A. L., Hornung, B., Rádi, K., Gengeliczki, Z., Sztáray, B., Juhász, T., Szeltner, Z., Harmat, V. & Polgár, L. (2007). *J. Mol. Biol.* **368**, 509–520.
- Krisco, A. & Radman, M. (2013). *Cold Spring Harb. Perspect. Biol.* **5**, a012765.
- Matthews, B. W. (1968). *J. Mol. Biol.* **33**, 491–497.
- McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C. & Read, R. J. (2007). *J. Appl. Cryst.* **40**, 658–674.
- Menyhárd, D. K., Kiss-Szemán, A., Tichy-Rács, É., Hornung, B., Rádi, K., Szeltner, Z., Domokos, K., Szamosi, I., Náray-Szabó, G., Polgár, L. & Harmat, V. (2013). *J. Biol. Chem.* **288**, 17884–17894.
- Rawlings, N. D., Waller, M., Barrett, A. J. & Bateman, A. (2014). *Nucleic Acids Res.* **42**, D503–D509.
- Santhoshkumar, P., Xie, L., Raju, M., Reneker, L. & Sharma, K. K. (2014). *J. Biol. Chem.* **289**, 9039–9052.
- Shan, L., Matthews, I. I. & Khosla, C. (2005). *Proc. Natl Acad. Sci. USA*, **102**, 3599–3604.
- Shimizu, K., Fujino, T., Ando, K., Hayakawa, M., Yasuda, H. & Kikugawa, K. (2003). *Biochem. Biophys. Res. Commun.* **304**, 766–771.
- Tan, S., Kern, R. C. & Selleck, W. (2005). *Protein Expr. Purif.* **40**, 385–395.
- Winn, M. D. *et al.* (2011). *Acta Cryst.* **D67**, 235–242.
- Yamin, R., Zhao, C., O’Connor, P. B., McKee, A. C. & Abraham, C. R. (2009). *Mol. Neurodegener.* **4**, 33.